Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1950 1
1951 6
1952 11
1953 4
1954 6
1955 5
1956 9
1957 11
1958 10
1959 9
1960 9
1961 12
1962 23
1964 1
1965 12
1966 23
1967 25
1968 24
1969 30
1970 17
1971 26
1972 29
1973 27
1974 25
1975 34
1976 28
1977 33
1978 34
1979 45
1980 33
1981 32
1982 39
1983 44
1984 57
1985 63
1986 67
1987 75
1988 82
1989 105
1990 104
1991 99
1992 104
1993 83
1994 117
1995 165
1996 135
1997 135
1998 124
1999 158
2000 158
2001 195
2002 246
2003 290
2004 288
2005 353
2006 414
2007 500
2008 452
2009 515
2010 570
2011 674
2012 679
2013 732
2014 711
2015 755
2016 832
2017 752
2018 782
2019 851
2020 1080
2021 1164
2022 1206
2023 1203
2024 539

Text availability

Article attribute

Article type

Publication date

Search Results

16,186 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy for the treatment of multiple myeloma.
Boussi LS, Avigan ZM, Rosenblatt J. Boussi LS, et al. Front Immunol. 2022 Oct 28;13:1027385. doi: 10.3389/fimmu.2022.1027385. eCollection 2022. Front Immunol. 2022. PMID: 36389674 Free PMC article. Review.
MRD in multiple myeloma: does CR really matter?
Paiva B, San-Miguel J, Avet-Loiseau H. Paiva B, et al. Blood. 2022 Dec 8;140(23):2423-2428. doi: 10.1182/blood.2022016170. Blood. 2022. PMID: 35560160 Free article. Review.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Kumar SK, et al. J Natl Compr Canc Netw. 2023 Dec;21(12):1281-1301. doi: 10.6004/jnccn.2023.0061. J Natl Compr Canc Netw. 2023. PMID: 38081133
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Sonneveld P, et al. Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21. Blood. 2016. PMID: 27002115 Free PMC article.
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma.
Teo WZY, Ong IYE, Tong JWY, Ong WL, Lin A, Song F, Tai BC, Ooi M, Seokojo CY, Chen Y, Nagarajan C, Chng WJ, de Mel S. Teo WZY, et al. Curr Hematol Malig Rep. 2023 Oct;18(5):190-200. doi: 10.1007/s11899-023-00704-9. Epub 2023 Jul 4. Curr Hematol Malig Rep. 2023. PMID: 37400631 Review.
16,186 results
You have reached the last available page of results. Please see the User Guide for more information.